Neil was previously Senior Vice-President, Discovery, at UCB S.A., overseeing an integrated portfolio of small molecule and antibody therapeutic projects in the areas of immunology and neurology. Neil and his teams have been responsible for transitioning 33 new chemical entities into development in immunology, oncology, bone and neurology.
Neil was one of the inventors of the drug Cimzia®, a novel pegylated anti-TNF. Prior to his role at UCB, Neil was Head of Discovery at Celltech R&D in the UK, during which time he was involved in the discovery and development of antibody and antibody fragment-based drugs including the first dual signalling domain chimeric receptor now known as second generation CAR-T.
Neil received a BSc in Biology from Edinburgh University and a PhD at the Institute of Biotechnology, University of Kent at Canterbury studying metabolic flux through amino acid biosynthesis pathways. Neil served as chair of the board of Beryllium BioSciences and is a non-exec member of the boards of the RNA Medicines company and Ondek. Neil chaired the UK ABPI innovation board from 2012 to 2018.
Olivia is a Principal at SV Health Investors and a former Partner at McKinsey and Company. She has over 15 years' experience working in healthcare and life sciences. She has led multi-year strategy and organisational efforts for biopharmaceutical, med devices and healthcare private equity clients. Olivia holds a degree in Medicine (MBChB) with honours and a first class degree in Pharmacology (BSc) from Bristol University, where she was awarded the Hans Heller Memorial Prize for outstanding performance.
Matthew joined Sitryx to lead its medicinal chemistry, CMC and intellectual property activities.
He has 19 years of experience in drug discovery and development, having formerly held positions as Head of Chemistry and Intellectual Property at TopiVert (London), Director of Drug Discovery at Oryzon (Barcelona) and Director of Medicinal Chemistry at Prosidion (Oxford). Matthew has successfully led research endeavours in multiple therapeutic areas, delivering compounds that have reached Phase 2 or further in oncology, immunology, metabolic disease, neurology and ophthalmology. Several of these compounds have been purchased by major pharma companies.
Matthew obtained degrees from the University of Glasgow (BSc), Columbia University (MA) and the University of Birmingham (PhD) prior to postdoctoral studies at UCLA with Nobel prize winner Sir Fraser Stoddart. He is a Chartered Chemist, a Fellow of The Royal Society of Chemistry, an author of more than 40 peer-reviewed publications and an inventor on over 75 patent applications.
Jonathan joined Sitryx in September 2020. He originally qualified in medicine and subsequently worked in the NHS for three years. He moved into investment banking and formed part of the Healthcare Corporate Finance and then Equity Research teams at Credit Suisse. Subsequent to this, Jonathan joined Nomura Code, before moving to Stifel to build the Healthcare team in London.
Patrik joined Sitryx as Head of Biology in April 2019 from UCB where he was Head of Immuno-Bone Discovery, responsible for small molecule and antibody projects from target identification to candidate nomination. Previously, he was managing molecular and cellular biology, primary pharmacology and screening in a range of disease areas including immunology, bone and neurology. Patrik has more than 15 years experience in drug discovery and development. He has lead several large and small molecule drug discovery programs targeting a number of disease indications and with a number of external partners. Patrik was instrumental in several Public Private Partnerships (IMI, Neuroallianz).
Patrik has a diploma in biology and received a PhD in molecular biology from EMBL Heidelberg and has published over two dozen peer-reviewed publications.
Tim joined Sitryx in November 2019 as Head of Translational Research, with over 14 years of drug development experience in the Translational Research and Early Clinical Development space and a demonstrated history of successfully progressing several new therapeutic entities into Ph1 and 2 clinical trials. Having formerly held positions as Translational Sciences Manager at GSK (UK), Director Clinical Strategy at UCB Celltech (UK) and most recently Chief Translational Research Officer at TxCell (France), Tim has over the years successfully lead the conception and implementation of biology and translational research strategies as well as the delivery of clinical and regulatory packages for several successful regulatory submissions. Most recently he drove the transitioning of a biotech from research to clinical development stage, exemplified by the successful progression of a World-first autologous CAR-Treg cell therapy into clinical testing.
Tim obtained degrees from Ruprecht Karls University in Heidelberg (BSc) and University College London (PhD) prior to postdoctoral studies at the University of Oxford.
Shelley joined Sitryx in June 2019 as Director of Operations. She has wide-ranging operational, scientific and strategic experience in Biotech drug discovery, life science equities and academic research. Previously Business Operations Manager at Immunocore, she fulfilled a pivotal role in the establishment and growth of the new Infectious Diseases Unit and the development of a portfolio of three programmes towards IND-enablement across multiple sites. Prior to this, Shelley was a public markets Equity Analyst (Biotechnology, Life Science, Technology).
Shelley obtained Bioscience degrees from the University of Oxford (MA, MSc, and DPhil) before completing studies as a Postdoctoral Research Fellow in emerging viral disease, molecular bioinformatics and novel sequencing technologies at the Natural History Museum, London. Shelley has published ~30 peer-reviewed papers, multiple first author.
Our experienced and respected management team have a proven track record guiding new companies through early inflection points.